		Clinical Trials			EMA/MHRA Approval	To Patients
		Phase I (safety)	Phase 2 (efficacy)	Phase 3 (proof)		
SMN-dependent	antisense oligonucleotide (targeting *SMN2*)					
	Ionis/Biogen **Spinraza/nusinersen**					
	Ionis/Biogen **Spinraza/nusinersen** (High Dose)					
	Ionis/Biogen **BIIB115/salanersen**					
	SMN1 gene replacement					
	Novartis Gene Therapies/Novartis **Zolgensma/onasemnogene abeparvovec** (intravenous)				**SMA Type 1 Only ***	
	Novartis Gene Therapies/Novartis **Itvisma/onasemnogene abeparvovec-brve** (intrathecal)					
	small molecule (targeting *SMN2*)					
	PTC/Roche **Evrysdi/risdiplam** (oral solution)					
	PTC/Roche **Evrysdi/risdiplam** (tablet form)					
Combination	combined treatments					
	Scholar Rock **SRK-015/apitegromab** + **nusinersen** or **risdiplam**					
	Biohaven Pharmaceuticals **taldefgrobep alfa** + **nusinersen** or **risdiplam** or **onasem. abeparv.**					
	Roche **GYM329 / Emugrobart** + PTC/Roche **risdiplam**					
SMN-independent	muscle-directed					
	NMD Pharma **NMD670**	**SMA Type 3 Only ***				

* Subject to country eligibility criteria